

Mylan India to sell Gilead drugs

OUR BUREAU

Mumbai, January 31

California-headquartered Gilead Sciences Inc has expanded its alliance with fellow US-based Mylan Inc by partnering exclusively with the latter's Indian subsidiary to sell its branded medicines in the country.

Mylan will market and distribute in India some of Gilead's medications, a note from Gilead said.

The medications include HIV

therapies Viread, Truvada and the newer single tablet regimen Stribild.

The agreement also covers AmBisome (amphotericin B liposome injection), a treatment for life-threatening, systemic fungal infections, which is also used to treat the parasitic disease visceral leishmaniasis. Viread is also included for its indication as a treatment for chronic hepatitis B virus (HBV) infection, the note said.

Gilead has partnered with Mylan since 2006, granting the company rights to manufacture and sell its own generic versions of licensed Gilead HIV therapies in India and up to 111 developing world countries where the HIV epidemic affects millions of people.

Mylan will continue to maintain these rights, in addition to those in this new agreement, the note said.

"The appointment of Mylan as

our branded medicine business partner in India is a result of their strong knowledge of the Indian healthcare system and demonstrated capabilities of supporting and distributing antiretroviral therapies," said Gregg H Alton, Gilead's Executive Vice-President of Corporate and Medical Affairs.

Mylan has established its footprint in India through acquisitions. It bought Hyderabad-based Matrix in 2006.

International co-operation
Company.